Several type I LRRK2 kinase inhibitors that bind to the LRRK2 ATP pocket and inhibit LRRK2-mediated Rab phosphorylation have advanced to clinical trials in PD (West and Schwarzschild, 2023). Here, LRRK2 is linked to Parkinson disease.